Intrastructural help in diversification of humoral autoimmune responses

Por FATENEJAD, S, CRAFT, J
Publicado em 1996

Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles.

Por Fatenejad, S, Mamula, M J, Craft, J
Publicado em 1993

Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis

Por Lukas, C, Landewé, R, Fatenejad, S, van der Heijde, D
Publicado em 2008

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial

Por van der Heijde, D, Landewé, R, van Vollenhoven, R, Fatenejad, S, Klareskog, L
Publicado em 2008

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

Por van der Heijde, D, Klareskog, L, Boers, M, Landewe, R, Codreanu, C, Bolosiu, H, Pedersen, R, Fatenejad, S, for, T
Publicado em 2005

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

Por van der Heijde, D, Klareskog, L, Singh, A, Tornero, J, Melo‐Gomes, J, Codreanu, C, Pedersen, R, Freundlich, B, Fatenejad, S
Publicado em 2006

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double‐blind comparison

Por Combe, B, Codreanu, C, Fiocco, U, Gaubitz, M, Geusens, P P, Kvien, T K, Pavelka, K, Sambrook, P N, Smolen, J S, Wajdula, J, Fatenejad, S
Publicado em 2006

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised...

Por Combe, B, Codreanu, C, Fiocco, U, Gaubitz, M, Geusens, P P, Kvien, T K, Pavelka, K, Sambrook, P N, Smolen, J S, Khandker, R, Singh, A, Wajdula, J, Fatenejad, S
Publicado em 2008

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

Por Calin, A, Dijkmans, B, Emery, P, Hakala, M, Kalden, J, Leirisalo-Repo, M, Mola, E, Salvarani, C, Sanmarti, R, Sany, J, Sibilia, J, Sieper, J, van der Linden, S, Veys, E, Appel, A, Fatenejad, S
Publicado em 2004

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

Por van der Heijde, D, Da Silva, J C, Dougados, M, Geher, P, van der Horst‐Bruinsma, I, Juanola, X, Olivieri, I, Raeman, F, Settas, L, Sieper, J, Szechinski, J, Walker, D, Boussuge, M‐P, Wajdula, J S, Paolozzi, L, Fatenejad, S
Publicado em 2006